Abivax SA (ABVX PA) stock market data APIs
€104.5015
0(0%)
as of April 17, 2026
Try our APIs with
free plan!
Abivax SA Financial Data Overview
Price chart is built with
Anychart
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Prev. Close
104.5015
Open
104.6315
High
106.8861
Low
102.1999
52 wk Range
5-132
Market Cap
8 302 M
Shares Outstanding
79 291 K
Revenue
4 570 K
EPS
-2.66
Beta
-0.102
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Abivax SA (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Abivax SA data using free add-ons & libraries
Get Abivax SA Fundamental Data
Abivax SA Fundamental data includes:
- Net Revenue: 4 570 K
- EBITDA: -244 983 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-23
- EPS/Forecast: -0.98
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abivax SA News
New
Medicxi Announces €500 Million Fund V
New fund will continue Medicxi's successful asset-centric company creation and investment strategy. LONDON, Nov. 14, 2025 /PRNewswire/ -- Medicxi, a leading European life sciences venture capital fir...
Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Abivax SA Sponsored ADR (ABVX) been one of those stocks this ...
2 Beaten-Down Stocks With Incredible Upside Potential
Key Points Viking Therapeutics' work in obesity treatment could lead to significant gains down the line. Recursion Pharmaceuticals could change the way drugs are developed. 10 stocks we like better t...
This Stock Is Up by 800% This Year -- but Is It a Buy?
Key Points Abivax's shares skyrocketed following positive clinical trial results for its lead candidate, obefazimod. This investigational medicine could prove more effective than existing drugs for u...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
